I-Mab Announces China NMPA Approval for Phase Ib Trial of Felzartamab in Systemic Lupus Erythematosus

I-Mab announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug application to initiate a phase Ib trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus.